Stephen P. Newman
Research Subjects
Research Interests
Stephen P. Newman has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Gary R. Pitcairn
1 shared publicationLisbeth Illum
IDentity
1 shared publicationRichard N. Dalby
1 shared publication
Latest Publications
- 1 January 2004
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (6) , 349-360
Spacer Devices for Metered Dose Inhalers
Spacer devices are attachments to the mouthpieces of pressurised metered dose inhalers (pMDIs), and range from tube spacers with a volume of <50mL to holding chambers with a volume of 750mL. Compared with a pMDI alone, spacers minimise coordination difficulties, reduce oropharyngeal deposition and often increase lung deposition. Spacers may not improve the clinical effect in patients able to use a pMDI properly, but may allow maintenance dosages of bronchodilators and corticosteroids to be reduced. Correct use of spacer devices is important, especially achieving control over electrostatic charge accumulation on the walls of plastic devices. In patients with severe acute asthma or severe chronic obstructive pulmonary disease, a pMDI plus large volume spacer may be a viable alternative to a nebuliser for delivering large bronchodilator doses. Although the addition of a spacer to every pMDI would not be justified, the use of large volume spacers has been recommended for any inhaled asthma drug in young children, and as a means of reducing systemic bioavailability of inhaled corticosteroids in adults and children alike.
- 1 January 2004
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (6) , 349-360
Spacer Devices for Metered Dose Inhalers
Spacer devices are attachments to the mouthpieces of pressurised metered dose inhalers (pMDIs), and range from tube spacers with a volume of <50mL to holding chambers with a volume of 750mL. Compared with a pMDI alone, spacers minimise coordination difficulties, reduce oropharyngeal deposition and often increase lung deposition. Spacers may not improve the clinical effect in patients able to use a pMDI properly, but may allow maintenance dosages of bronchodilators and corticosteroids to be reduced. Correct use of spacer devices is important, especially achieving control over electrostatic charge accumulation on the walls of plastic devices. In patients with severe acute asthma or severe chronic obstructive pulmonary disease, a pMDI plus large volume spacer may be a viable alternative to a nebuliser for delivering large bronchodilator doses. Although the addition of a spacer to every pMDI would not be justified, the use of large volume spacers has been recommended for any inhaled asthma drug in young children, and as a means of reducing systemic bioavailability of inhaled corticosteroids in adults and children alike.
- 1 January 2004
- Published by Springer Nature in American Journal of Drug Delivery
- Vol. 2 (2) , 101-112
Radionuclide Imaging Studies in the Assessment of Nasal Drug Delivery in Humans
- 1 January 2004
- Published by Springer Nature in American Journal of Drug Delivery
- Vol. 2 (2) , 101-112
Radionuclide Imaging Studies in the Assessment of Nasal Drug Delivery in Humans
- 1 January 2004
- Published by Begell House Inc. Publishers in Critical Reviews™ in Therapeutic Drug Carrier Systems
- Vol. 21 (1) , 21-66
Delivery to the Nasal Cavity: In Vitro and In Vivo Assessment
- 1 January 2004
- Published by Begell House Inc. Publishers in Critical Reviews™ in Therapeutic Drug Carrier Systems
- Vol. 21 (1) , 21-66
Delivery to the Nasal Cavity: In Vitro and In Vivo Assessment
- 1 January 2004
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 4 (1) , 23-33
Dry powder inhalers for optimal drug delivery
Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30 years. In the last decade there has been a big increase in DPI development, resulting partly from recognised limitations in other types of inhaler device. Many companies are developing DPIs for asthma and chronic obstructive pulmonary disease (COPD) therapy, and there is increasing recognition of the potential role of DPI systems for other therapies, such as inhaled antibiotics and peptides/proteins. Optimised drug delivery may be achieved not only by improvements to devices, but also via more sophisticated formulations that disperse easily in the inhaled air-stream and which may often be delivered by relatively simple inhaler devices. DPIs could become the device category of choice for a wide range of inhaled therapies, involving both local and systemic drug delivery.
- 1 January 2004
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 4 (1) , 23-33
Dry powder inhalers for optimal drug delivery
Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30 years. In the last decade there has been a big increase in DPI development, resulting partly from recognised limitations in other types of inhaler device. Many companies are developing DPIs for asthma and chronic obstructive pulmonary disease (COPD) therapy, and there is increasing recognition of the potential role of DPI systems for other therapies, such as inhaled antibiotics and peptides/proteins. Optimised drug delivery may be achieved not only by improvements to devices, but also via more sophisticated formulations that disperse easily in the inhaled air-stream and which may often be delivered by relatively simple inhaler devices. DPIs could become the device category of choice for a wide range of inhaled therapies, involving both local and systemic drug delivery.
- 1 January 2003
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (6) , 529-544
Deposition and Effects of Inhaled Corticosteroids
Inhaled corticosteroids are now recommended as maintenance therapy for all but the mildest cases of asthma, and may be delivered by a variety of devices and formulations. Drug delivery may be assessed by both in vitro and in vivo methods. Although drug deposition in the lungs is expected to predict clinical response, this relationship is often masked by the flat nature of corticosteroid dose-response curves. The effects of inhaled corticosteroids depend not only upon the pharmacology of the drug being administered, but also upon its delivery system, with more efficient devices not only improving therapeutic effect but also potentially increasing systemic adverse effects. Modern delivery systems that enhance drug targeting to the lungs make it possible to use lower dosages of inhaled corticosteroid, such that the clinical response is maintained but systemic exposure reduced.
- 1 January 2003
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 42 (6) , 529-544
Deposition and Effects of Inhaled Corticosteroids
Inhaled corticosteroids are now recommended as maintenance therapy for all but the mildest cases of asthma, and may be delivered by a variety of devices and formulations. Drug delivery may be assessed by both in vitro and in vivo methods. Although drug deposition in the lungs is expected to predict clinical response, this relationship is often masked by the flat nature of corticosteroid dose-response curves. The effects of inhaled corticosteroids depend not only upon the pharmacology of the drug being administered, but also upon its delivery system, with more efficient devices not only improving therapeutic effect but also potentially increasing systemic adverse effects. Modern delivery systems that enhance drug targeting to the lungs make it possible to use lower dosages of inhaled corticosteroid, such that the clinical response is maintained but systemic exposure reduced.